Overview

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

Status:
Not yet recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open, multi-center clinical study of nab-paclitaxel as the therapy ER+/HER2- recurrent metastatic breast cancer。
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel